The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Kenkare-Mitra Sara | Director | Grant(A) | 84K | — | $0 |
| May 14, 2026 | Kenkare-Mitra Sara | Director | Grant(A) | 42K | — | $0 |
| May 14, 2026 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 170K | — | $0 |
| May 14, 2026 | Gupta Shalabh K. | CEO, Director | Grant(A) | 762K | — | $0 |
| May 14, 2026 | Laumas Sandeep | Director | Grant(A) | 84K | — | $0 |
| May 14, 2026 | Laumas Sandeep | Director | Grant(A) | 42K | — | $0 |
| May 14, 2026 | Townsend John | CFO | Grant(A) | 170K | — | $0 |
| May 14, 2026 | Jermasek Douglas | EVP, Corporate Strategy | Grant(A) | 170K | — | $0 |
| May 14, 2026 | Townsend John | CFO | Grant(A) | 170K | — | $0 |
| May 14, 2026 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 170K | — | $0 |
| May 14, 2026 | Jermasek Douglas | EVP, Corporate Strategy | Grant(A) | 170K | — | $0 |
| May 14, 2026 | Gupta Shalabh K. | CEO, Director | Grant(A) | 762K | — | $0 |
| May 14, 2026 | Kenkare-Mitra Sara | Director | Grant(A) | 48K | — | $0 |
| May 14, 2026 | Laumas Sandeep | Director | Grant(A) | 48K | — | $0 |
| Aug 25, 2025 | Aggarwal Gaurav | Director | Conversion(C) | 653K | — | — |
| Aug 25, 2025 | Aggarwal Gaurav | Director | Disposed to issuer(D) | 3K | $1,000.00 | $3.2M |
| Jul 28, 2025 | Jermasek Douglas | EVP of Corporate Strategy | Grant(A) | 10K | — | $0 |
| Jul 28, 2025 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 90K | — | $0 |
| Jul 28, 2025 | Townsend John | Chief Financial Officer | Grant(A) | 10K | — | $0 |
| Jul 28, 2025 | Gupta Shalabh K. | CEO, Director | Grant(A) | 325K | — | $0 |
| Jul 28, 2025 | Kenkare-Mitra Sara | Director | Grant(A) | 21K | — | $0 |
| Jul 28, 2025 | Laumas Sandeep | Director | Grant(A) | 21K | — | $0 |
| Jul 28, 2025 | Aggarwal Gaurav | Director | Grant(A) | 21K | — | $0 |
| Feb 18, 2025 | Aggarwal Gaurav | Director | Conversion(C) | 1.4M | — | — |
| Feb 18, 2025 | Aggarwal Gaurav | Director | Disposed to issuer(D) | 686 | $1,000.00 | $686K |
| Oct 9, 2024 | Aggarwal Gaurav | Director | Conversion(C) | 5.5M | — | — |
| Oct 9, 2024 | Aggarwal Gaurav | Director | Disposed to issuer(D) | 3K | $1,000.00 | $2.7M |
| Aug 12, 2024 | Gupta Shalabh K. | CEO, Director | Grant(A) | 233K | — | $0 |
| Aug 12, 2024 | Jermasek Douglas | EVP of Corporate Strategy | Grant(A) | 82K | — | $0 |
| Aug 12, 2024 | Townsend John | Chief Financial Officer | Grant(A) | 40K | — | $0 |
| Aug 12, 2024 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 82K | — | $0 |
| Apr 15, 2024 | Gupta Shalabh K. | CEO, Director, 10% Owner | Grant(A) | 1.3M | — | $0 |
| Apr 15, 2024 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 463K | — | $0 |
| Apr 15, 2024 | Jermasek Douglas | EVP of Corporate Strategy | Grant(A) | 463K | — | $0 |
| Apr 15, 2024 | Townsend John | Chief Financial Officer | Grant(A) | 228K | — | $0 |
| Sep 5, 2023 | Aggarwal Gaurav | Director | Grant(A) | 180K | — | $0 |
| Sep 5, 2023 | Ryan John L | Director | Grant(A) | 112K | — | $0 |
| Sep 5, 2023 | Kenkare-Mitra Sara | Director | Grant(A) | 180K | — | $0 |
| Sep 5, 2023 | Laumas Sandeep | Director | Grant(A) | 189K | — | $0 |
| Aug 28, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Grant(A) | 1.4M | — | $0 |
| Aug 28, 2023 | Townsend John | Chief Financial Officer | Grant(A) | 570K | — | $0 |
| Aug 28, 2023 | Gupta Shalabh K. | CEO, Director | Grant(A) | 4.7M | — | $0 |
| Aug 28, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 1.4M | — | $0 |
| Jul 11, 2023 | Gupta Shalabh K. | CEO, Director | Option exercise(M) | 105K | — | — |
| Jul 11, 2023 | Gupta Shalabh K. | CEO, Director | Option exercise(M) | 115K | — | — |
| Jul 11, 2023 | Gupta Shalabh K. | CEO, Director | Option exercise(M) | 79K | — | — |
| Jul 11, 2023 | Gupta Shalabh K. | CEO, Director | Option exercise(M) | 50 | $1,000.00 | $50K |
| Jul 11, 2023 | Gupta Shalabh K. | CEO, Director | Option exercise(M) | 72K | — | — |
| Jul 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Option exercise(M) | 42K | — | — |
| Jul 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Option exercise(M) | 46K | — | — |
| Jul 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Option exercise(M) | 32K | — | — |
| Jul 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Option exercise(M) | 20 | $1,000.00 | $20K |
| Jul 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Option exercise(M) | 29K | — | — |
| Jul 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Option exercise(M) | 105K | — | — |
| Jul 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Option exercise(M) | 50 | $1,000.00 | $50K |
| Jul 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Option exercise(M) | 115K | — | — |
| Jul 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Option exercise(M) | 79K | — | — |
| Jul 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Option exercise(M) | 72K | — | — |
| Jul 11, 2023 | Aggarwal Gaurav | Director | Conversion(C) | 3.5M | — | — |
| Jul 11, 2023 | Aggarwal Gaurav | Director | Conversion(C) | 8K | $1,000.00 | $8.1M |
| Jul 11, 2023 | Aggarwal Gaurav | Director | Conversion(C) | 13.4M | — | $0 |
| Jul 11, 2023 | Aggarwal Gaurav | Director | Conversion(C) | 18.6M | — | $0 |
| Jul 11, 2023 | Aggarwal Gaurav | Director | Conversion(C) | 11.6M | — | $0 |
| Jul 11, 2023 | Aggarwal Gaurav | Director | Conversion(C) | 12.8M | — | $0 |
| Mar 8, 2023 | Jermasek Douglas | EVP of Corporate Strategy | Grant(A) | 50 | $1,000.00 | $50K |
| Mar 8, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 20 | $1,000.00 | $20K |
| Mar 8, 2023 | Gupta Shalabh K. | CEO, Director | Grant(A) | 50 | $1,000.00 | $50K |
| Mar 8, 2023 | Aggarwal Gaurav | Director | Grant(A) | 8K | $1,000.00 | $8.1M |
| Nov 21, 2022 | Gupta Shalabh K. | CEO, Director | Grant(A) | 86K | — | $0 |
| Nov 21, 2022 | Jermasek Douglas | EVP of Corporate Strategy | Grant(A) | 55K | — | $0 |
| Nov 21, 2022 | Townsend John | Chief Financial Officer | Grant(A) | 35K | — | $0 |
| Nov 21, 2022 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 28K | — | $0 |
| Jul 15, 2022 | Schiller Brigitte | Director | Option exercise(M) | 27K | — | $0 |
| Jul 15, 2022 | Schiller Brigitte | Director | Option exercise(M) | 27K | — | $0 |
| May 16, 2022 | Schiller Brigitte | Director | Buy(P) | 15K | $0.83 | $12K |
| Jul 15, 2021 | Gupta Shalabh K. | CEO, Director | Grant(A) | 116K | — | $0 |
| Jul 15, 2021 | Townsend John | Chief Financial Officer | Grant(A) | 19K | — | $0 |
| Jul 15, 2021 | Gupta Pramod | EVP, Pharmaceuticals and BD | Grant(A) | 35K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2019-12-30 → 2026-08-06. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for UNCY